Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular Interventions: Device: 166Holmium microspheres (QuiremSpheres ®) Sponsors: Imperial College London; Terumo Europe N.V. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Conditions: Hepatocellular Carcinoma; Adjuvant Immunotherapy; Checkpoint Inhibitor Interventions: Drug: Anti-PD-1 monoclonal antibody Sponsors: Chen Xiaoping Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Conditions: Hepatocellular Carcinoma Resectable Sponsors: National Cancer Centre, Singapore; Singapore General Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Phase Ib/II Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Valemetostat; Drug: Atezolizumab; Drug: Bevacizumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Procedure: TOMOX-HAIC; Drug: Sintilimab; Drug: Bevacizumab Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Hypersplenism
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Combination Product: Splenectomy+Targeted therapy+ Immunotherapy Sponsors: Zhiyong Huang; Wuhan Union Hospital, China; Wuhan University; Renmin Hospital of Wuhan University; Taihe Hospital; Hubei Cancer Hospital; Xiangyang Central Hospital of Hubei Province; Wuhan Central Hospital; The Third People ' s Hospital of Yichang City Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+regorafenib Sponsors: Meng Chao Hepatobiliary Hospital of Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy
Conditions: Liver Neoplasms Interventions: Other: late-evening snacks Sponsors: DU Yao Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Sponsors: Hebei Medical University Third Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Conditions: Liver Cirrhosis; Hepatic Cell Carcinoma; Portal Hypertension Interventions: Drug: Injection of a gadolinium contrast agen; Drug: Radiotracer Injection; Diagnostic Test: Imaging Sponsors: Massachusetts General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Conditions: Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignan...
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
Conditions: Hepatocellular Carcinoma Non-resectable Interventions: Procedure: Len+DEB-TACE+HAIC; Procedure: Len+DEB-TACE Sponsors: Second Affiliated Hospital of Guangzhou Medical University; Zhongshan People ' s Hospital, Guangdong, China; Affiliate Hospital of Guangdong Medical University; Jieyang People ' s Hospital; Huizhou Municipal Central Hospital; Guangzhou Development District Hospital; Shenzhen Traditional Chinese Medicine Hospital; First People ' s Hospital of Foshan Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
Conditions: Hepatocellular Carcinoma; Liver Cancer Stage IV; Pulmonary Metastases; Cadonilimab; Bevacizumab; Cryoablation Interventions: Drug: Cadonilimab; Drug: Bevacizumab; Procedure: Cryoablation Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Targeted Navigation in Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatobiliary Cancer Interventions: Behavioral: Target Navigation Pilot Program Sponsors: University of Miami; The V Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
Conditions: Hepatocellular Carcinoma; Radiotherapy Interventions: Radiation: radiotherapy Sponsors: Shandong Cancer Hospital and Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
